Literature DB >> 2659281

The pathology of murine myelogenous leukemias.

A S Perkins.   

Abstract

Murine myelogenous leukemias can be classified into several distinct subgroups based on morphology, cytochemical staining, and immunoreactivity. The leukemias invariably involve the spleen and the extent of infiltration into other tissues is variable. The myelogenous nature of the leukemia is readily apparent in well-differentiated leukemias on the basis of morphology; with poorly differentiated leukemias, positive staining with chloroacetate esterase, nonspecific esterase, and certain monoclonal antibodies such as Mac-1, is helpful to establish myelogenous differentiation. Subgrouping of myelogenous leukemias depends on the presence or absence of monocytic differentiation, as ascertained by staining with Mac-2, electron microscopy or phagocytosis. Leukemias showing no monocytic differentiation can be classified as myeloblastic, corresponding to the FAB M1 and M2 subtypes in humans. Leukemias exhibiting both monocytic and granulocytic features are myelomonocytic, corresponding to the FAB M4 subtype. Tumors with only monocyte differentiation arise primarily as solid tumors in mice, and a leukemic phase is variable.

Entities:  

Mesh:

Year:  1989        PMID: 2659281     DOI: 10.1007/978-3-642-74623-9_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  2 in total

1.  Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia.

Authors:  S M Blaydes; S C Kogan; B T Truong; D J Gilbert; N A Jenkins; N G Copeland; D A Largaespada; C I Brannan
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 2.  A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology.

Authors:  Hala Skayneh; Batoul Jishi; Rita Hleihel; Maguy Hamieh; Nadine Darwiche; Ali Bazarbachi; Marwan El Sabban; Hiba El Hajj
Journal:  Genes (Basel)       Date:  2019-08-13       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.